Effects of Lumacaftor‐Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis

Rationale: The combination of the CFTR (cystic fibrosis transmembrane conductance regulator) corrector lumacaftor with the potentiator ivacaftor has been approved for the treatment of patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. The phase 3 trials examined clinical outcomes but did not evaluate CFTR function in patients. Objectives: To examine the effect of lumacaftor‐ivacaftor on biomarkers of CFTR function in Phe508del homozygous patients with cystic fibrosis aged 12 years and older. Methods: This prospective observational study assessed clinical outcomes including FEV1% predicted and body mass index, and CFTR biomarkers including sweat chloride concentration, nasal potential difference, and intestinal current measurement before and 8‐16 weeks after initiation of lumacaftor‐ivacaftor. Measurements and Main Results: A total of 53 patients were enrolled in the study, and 52 patients had baseline and follow‐up measurements. After initiation of lumacaftor‐ivacaftor sweat chloride concentrations were reduced by 17.8 mmol/L (interquartile range [IQR], −25.9 to −6.1; P < 0.001), nasal potential difference showed partial rescue of CFTR function in nasal epithelia to a level of 10.2% (IQR, 0.0‐26.1; P < 0.011), and intestinal current measurement showed functional improvement in rectal epithelia to a level of 17.7% of normal (IQR, 10.8‐29.0; P < 0.001). All patients improved in at least one CFTR biomarker, but no correlations were found between CFTR biomarker responses and clinical outcomes. Conclusions: Lumacaftor‐ivacaftor results in partial rescue of Phe508del CFTR function to levels comparable to the lower range of CFTR activity found in patients with residual function mutations. Functional improvement was detected even in the absence of short‐term improvement of FEV1% predicted and body mass index. Clinical trial registered with www.clinicaltrials.gov (NCT02807415).

[1]  M. Lopes-Pacheco.  CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine , 2020, Frontiers in Pharmacology.

[2]  S. Rowe,et al.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. , 2019, American journal of respiratory and critical care medicine.

[3]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Residual‐Function Heterozygotes with Cystic Fibrosis , 2017, The New England journal of medicine.

[4]  M. Maher,et al.  CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra‐Low‐Dose Chest CT Scores After CFTR Modulation With Ivacaftor , 2017, Chest.

[5]  F. Vermeulen,et al.  A multiple reader scoring system for Nasal Potential Difference parameters. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  S. Stanojevic,et al.  Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. , 2017, The Lancet. Respiratory medicine.

[7]  L. Hoffman,et al.  Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections , 2017, American journal of respiratory and critical care medicine.

[8]  P. Sly,et al.  Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It? , 2017, American journal of respiratory and critical care medicine.

[9]  S. Stanojevic,et al.  Progression of Lung Disease in Preschool Patients with Cystic Fibrosis , 2017, American journal of respiratory and critical care medicine.

[10]  M. Welsh,et al.  AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. , 2017, American journal of respiratory and critical care medicine.

[11]  C. Goss,et al.  Cystic Fibrosis: The Dawn of a New Therapeutic Era , 2017, American journal of respiratory and critical care medicine.

[12]  M. Rosenfeld,et al.  Lumacaftor/Ivacaftor in Patients Aged 6‐11 Years with Cystic Fibrosis and Homozygous for F508del‐CFTR , 2017, American journal of respiratory and critical care medicine.

[13]  C. Goss,et al.  Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. , 2017, The Lancet. Respiratory medicine.

[14]  J. Rommens,et al.  Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis. , 2016, American journal of respiratory and critical care medicine.

[15]  Hans-Ulrich Kauczor,et al.  Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis , 2016, American journal of respiratory and critical care medicine.

[16]  A. Heinzmann,et al.  Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. , 2015, American journal of respiratory and critical care medicine.

[17]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[18]  Umer Khan,et al.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[19]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[20]  D. Hartl,et al.  CFTR: cystic fibrosis and beyond , 2014, European Respiratory Journal.

[21]  J. Clancy,et al.  Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[22]  R. Szczesniak,et al.  Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function , 2013, PloS one.

[23]  J. Clancy,et al.  Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation , 2013, PloS one.

[24]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[25]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[26]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[27]  M. Amaral,et al.  The K+ Channel Opener 1-EBIO Potentiates Residual Function of Mutant CFTR in Rectal Biopsies from Cystic Fibrosis Patients , 2011, PloS one.

[28]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[29]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[30]  F. Stanke,et al.  Functional analysis of F508del CFTR in native human colon. , 2010, Biochimica et biophysica acta.

[31]  Milan Macek,et al.  Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. , 2010, American journal of respiratory and critical care medicine.

[32]  Antonia Zapf,et al.  Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data , 2010, Thorax.

[33]  H. Blau,et al.  Diversity of the basic defect of homozygous CFTR mutation genotypes in humans , 2007, Journal of Medical Genetics.

[34]  M. Corey,et al.  Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. , 2006, American journal of respiratory and critical care medicine.

[35]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[36]  J. Riordan,et al.  Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. , 2005, Molecular biology of the cell.

[37]  M. Amaral,et al.  CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. , 2004, Gastroenterology.

[38]  Hong Yang,et al.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. , 2002, The Journal of clinical investigation.

[39]  B. Tümmler,et al.  Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. , 2001, The Journal of clinical investigation.

[40]  B. Tümmler,et al.  Residual chloride secretion in intestinal tissue of ΔF508 homozygous twins and siblings with cystic fibrosis , 2000 .

[41]  B. Tümmler,et al.  ΔF508 CFTR protein expression in tissues from patients with cystic fibrosis , 1999 .

[42]  H. D. de Jonge,et al.  Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. , 1991, Gastroenterology.

[43]  F. van Goor,et al.  Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[44]  C. Goss,et al.  Cystic fibrosis , 2015, Nature Reviews Disease Primers.

[45]  S. Willsie.  A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation , 2012 .

[46]  K. Rabe,et al.  [The German centre for lung research - translational research for the prevention, diagnosis and treatment of respiratory diseases]. , 2012, Pneumologie.

[47]  J. Clancy,et al.  Nasal potential difference measurements to assess CFTR ion channel activity. , 2011, Methods in molecular biology.

[48]  J. Riordan,et al.  The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. , 2004, Gastroenterology.

[49]  P. Quinton,et al.  Bumetanide blocks CFTR G Cl in the native sweat duct. , 1999, American journal of physiology. Cell physiology.